Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

February 3, 2026 updated by: GlaxoSmithKline

A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

236

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Antwerp, Belgium, 2650
        • GSK Investigational Site
      • Brussels, Belgium, 1000
        • GSK Investigational Site
      • Brussels, Belgium, 1070
        • GSK Investigational Site
      • Edegem, Belgium, 2650
        • GSK Investigational Site
      • Ghent, Belgium, 9000
        • GSK Investigational Site
      • Leuven, Belgium, 3000
        • GSK Investigational Site
  • France
      • Clichy, France, 92118
        • GSK Investigational Site
      • Créteil, France, 94010
        • GSK Investigational Site
      • Lyon, France, 69317
        • GSK Investigational Site
      • Strasbourg, France, 67091
        • GSK Investigational Site
  • Germany
      • Berlin, Germany, 10787
        • GSK Investigational Site
      • Bonn, Germany, 53127
        • GSK Investigational Site
      • Essen, Germany, 45122
        • GSK Investigational Site
      • Frankfurt, Germany, 60590
        • GSK Investigational Site
      • Hamburg, Germany, 20246
        • GSK Investigational Site
      • Mainz, Germany, 55131
        • GSK Investigational Site
  • Hong Kong
      • Pokfulam, Hong Kong
        • GSK Investigational Site
  • Poland
      • Krakow, Poland, 31-202
        • GSK Investigational Site
      • Mysłowice, Poland, 41-400
        • GSK Investigational Site
      • Poznan, Poland, 60-185
        • GSK Investigational Site
      • Łańcut, Poland, 37-100
        • GSK Investigational Site
  • Spain
      • Barcelona, Spain, 08907
        • GSK Investigational Site
      • Barcelona, Spain, 08011
        • GSK Investigational Site
      • Córdoba, Spain, 14004
        • GSK Investigational Site
      • Granada, Spain, 18016
        • GSK Investigational Site
      • Madrid, Spain, 28006
        • GSK Investigational Site
      • Madrid, Spain, 28007
        • GSK Investigational Site
      • Madrid, Spain, 28034
        • GSK Investigational Site
      • Madrid, Spain, 28222
        • GSK Investigational Site
      • Palma de Mallorca, Spain, 07120
        • GSK Investigational Site
      • Santander, Spain, 39008
        • GSK Investigational Site
      • Seville, Spain, 41013
        • GSK Investigational Site
      • TorrejOn Ardoz Madrid, Spain, 28850
        • GSK Investigational Site
  • Taiwan
      • Taichung, Taiwan, 40447
        • GSK Investigational Site
      • Taichung, Taiwan, 40705
        • GSK Investigational Site
      • Tainan, Taiwan, 704
        • GSK Investigational Site
      • Taipei, Taiwan, 112
        • GSK Investigational Site
      • Taoyuan District, Taiwan, 333
        • GSK Investigational Site
  • Thailand
      • Bangkok, Thailand, 10330
        • GSK Investigational Site
      • Chiang Mai, Thailand, 50200
        • GSK Investigational Site
  • United Kingdom
      • London, United Kingdom, E1 1BB
        • GSK Investigational Site
      • London, United Kingdom, SW17 0QT
        • GSK Investigational Site
      • Nottingham, United Kingdom, NG7 2UH
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the patient prior to performing any study specific procedure.
  • A male or female between, and including, 18 and 65 years of age at the time of the first vaccination.
  • Female patients of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral ovariectomy or post-menopause.

  • Female patients of childbearing potential may be enrolled in the study if the patient:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test at Screening, and
    • has agreed to continue adequate contraception from Screening until 12 weeks after completion of the vaccination series

  • Male patients:

    • with documented bilateral vasectomy and resultant azoospermia, bilateral orchiectomy or azoospermia, or
    • who agree to practice abstinence from penile-vaginal intercourse (when this is their preferred and usual lifestyle) or use condoms from Screening until 12 weeks after completion of the vaccination series.
  • Chronic Hepatitis B (CHB) patient, under and adherent to treatment with a nucleo(s)tide analogue with high barrier to resistance given as per approved label/dosage for at least 24 months.
  • Documented medical history of Hepatitis B Virus e Antigen (HBeAg)-negative CHB prior to onset of NA therapy (applicable to all patients in Step A and Step B and to some patients in Step C) or documented medical history of HBeAg-negative CHB over a period of at least 24 months prior screening (applicable to some patients in Step C only).
  • Documented HBV viral suppression as per local clinical diagnosis within the previous 24 months AND at Screening test HBV DNA < 10 IU/mL. If no results are available, two Screening tests need to be performed at least 2 weeks apart. Small fluctuations of HBV DNA (≤ 10 x LLOQ; LLOQ defined by laboratory that performed testing) are allowed provided HBV DNA is < 10 IU/mL at Screening and was clearly not rising during the previous 24 months.
  • Documented normal level of ALT as per local clinical diagnosis within the previous 24 months AND at Screening test ALT < 48U/L. Small fluctuations of ALT (≤ 1.5 X ULN) are allowed provided ALT< 48 U/L at Screening. If no results are available, two Screening tests need to be performed at least 2 weeks apart. ULN are to be defined according to local laboratory reference range.
  • No clinical diagnosis of cirrhosis (e.g. F4 by METAVIR scoring system or ≥ 6 by Ishak scoring system or FibroScan TE score > 12.5 kPa) within the previous 24 months.
  • FibroScan Transient Elastography (TE) score < 9.6 kPa and FibroTest score < 0.59 at Screening. A patient with one of these parameters out of range, but having the liver biopsy within 12 months before screening that showed F0-2 by METAVIR scoring system or stage 0-4 by Ishak scoring system, can be included.
  • HBsAg concentration > 50 IU/mL and anti-HBs negative at Screening.
  • Anti-HBc positive at Screening.
  • HBeAg-negative at Screening.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 10 mg/day or equivalent. Inhaled and topical steroids are allowed.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.
  • Use of systemic cytotoxic agents, chronic antiviral agents or Chinese herbal medicines which, in the opinion of the investigator, may have activity against HBV within the previous 6 months prior to randomization into this study. Antiviral treatment/prevention for influenza or herpes simplex virus is allowed.
  • Administration of adenovirus/adenovector-based or MVA-based vaccine within the last 12 months except for adenovirus/adenovector-based COVID-19 vaccines that could be administered up to 30 days prior to the first study vaccine dose (applicable for all patients except for the patients in France) OR Administration of adenovirus/adenovector-based or MVA-based vaccine within the last 12 months (applicable for the patients in France only).
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days before each dose and ending 30 days after each dose of vaccines, with the exception of influenza vaccine that may be given at any time except within a 7-day period before or after each vaccine dose and COVID-19 vaccine that may be given at any time except within a 30-day period before or after each vaccine dose apart from COVID-19 mRNA based-vaccines that may be administered any time except for the period of 14 days before and 30 days after each study vaccine dose. Note: If the type of COVID-19 vaccine is unknown, the allowed interval of 30 days before or after each study vaccine dose should be followed.
  • Treatment with nephrotoxic drugs or competitors of renal excretion within 2 months prior to Screening or the expectation that patient will receive any of these during the course of the study. TAF/TDF given as NA therapy is allowed.
  • Concurrently participating in another clinical study, at any time during the study period, in which the patient has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Medical history of cirrhosis or hepatic decompensation.
  • Planned for liver transplantation or previous liver transplantation.
  • Personal or family (first degree) history of autoimmune disease.
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
  • Evidence of Hepatitis C Virus and hepatitis D Virus infection.

  • Suspicion of or confirmed Hepatocellular Carcinoma or any other liver cancer in medical history or at Screening:

    • Suspicious foci at liver imaging exam
    • Elevated α-fetoprotein > 50 ng/mL.
  • Documented evidence of other currently active cause of hepatitis.
  • Hematology and biochemistry parameters outside normal clinical range at Screening:

Biochemistry:

  • Glomerular filtration rate < 60 mL/min
  • Bilirubin > 27.5 µmol/L unless *or the diagnosis of Gilbert Syndrome has been established and confirmed by the Investigator
  • GGT > 65 U/L (males) or > 45 U/L (females)*
  • ALT > 48 U/L
  • AST > 42 U/L*
  • ALP > 125 U/L*

Hematology:

  • Hemoglobin < 12.0 g/dL (females) or < 13.5 g/dL (males)*
  • Red blood cell count < 3.9 x 10^6 cells/mm^3 (females) or < 4.4 x 10^6 cells/mm^3 (males)*
  • White blood cell count < 3,500 cells/mm^3 or > 12,000 cells/mm^3*
  • Platelets < 140,000 cells/mm^3

  • INR > 1.32 (i.e. 1.1 x ULN) *unless it is considered as clinically not significant by the Investigator

    • Known diabetes Type I.
    • Body Mass Index > 35 kg/m^2 at Screening.
    • Any serious or active medical or psychiatric illnesses other than chronic hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol.
    • History of or current drug abuse and/or excess of alcohol consumption as defined per local guidelines.
    • HIV-positive patient.
    • Pregnant or lactating female.
    • Female planning to become pregnant or planning to discontinue contraceptive precautions in the period starting from the Screening Visit up to 12 weeks post-last vaccination visit.
    • Fever and or acute minor illness may be enrolled for Screening at the discretion of the investigator, provided that the condition is resolved at the time of vaccination.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Step A: Group A1
Participants were scheduled to receive one dose of Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation on Day 1, one dose of Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation on Day 57, and two doses of HBc-HBs/AS01B-4 low dose formulation, one on Day 113 and one on Day 169.
Biological: ChAd155-hIi-HBV low dose formulation
Participants in group A1 were scheduled to receive one dose of ChAd155-hIi-HBV low dose formulation on Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
Biological: HBc-HBs/AS01B-4 low dose formulation
Participants in group A1 were scheduled to receive two doses of HBc-HBs/AS01B-4 low dose formulation, one on Day 113 and one on Day 169, and participants in group A2 were scheduled to receive four doses of the HBc-HBs/AS01B-4 low dose formulation, one dose each on Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Biological: MVA-HBV low dose formulation
Participants in group A1 were scheduled to receive one dose of MVA-HBV low dose formulation on Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
Active Comparator: Step A: Group A2
Participants were scheduled to receive four doses of HBc-HBs/AS01B-4 low dose formulation, one dose each on Day 1, Day 57, Day 113 and Day 169.
Biological: HBc-HBs/AS01B-4 low dose formulation
Participants in group A1 were scheduled to receive two doses of HBc-HBs/AS01B-4 low dose formulation, one on Day 113 and one on Day 169, and participants in group A2 were scheduled to receive four doses of the HBc-HBs/AS01B-4 low dose formulation, one dose each on Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Placebo Comparator: Step A: Group A3
Participants were scheduled to receive four doses of placebo, one dose each on Day 1, Day 57, Day 113 and Day 169.
Drug: Placebo
Participants in group A3 were scheduled to receive four doses of placebo, one each on Days 1, 57, 113 and 169 and participants in group B3 were scheduled to receive two doses of placebo one each on Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C2 were scheduled to receive two co-administered doses of placebo on Day 1 and two co-administered doses of placebo on Day 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Experimental: Step B: Group B1
Participants were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1, one dose of MVA-HBV high dose formulation on Day 57, and two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169.
Biological: ChAd155-hIi-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

Biological: HBc-HBs/AS01B-4 high dose formulation
Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Biological: MVA-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.
Active Comparator: Step B: Group B2
Participants were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Day 1, Day 57, Day 113 and Day 169.
Biological: HBc-HBs/AS01B-4 high dose formulation
Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Active Comparator: Step B: Group B3
Participants were scheduled to receive two doses of placebo, one on Day 1 and one on Day 57, one dose of ChAd155-hIi-HBV high dose formulation on Day 113 and one dose of MVA-HBV high dose formulation on Day 169.
Drug: Placebo
Participants in group A3 were scheduled to receive four doses of placebo, one each on Days 1, 57, 113 and 169 and participants in group B3 were scheduled to receive two doses of placebo one each on Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C2 were scheduled to receive two co-administered doses of placebo on Day 1 and two co-administered doses of placebo on Day 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Biological: ChAd155-hIi-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

Biological: MVA-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.
Experimental: Step C: Group C1
Participants were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with one dose of HBc-HBs/AS01B-4 high dose formulation on Day 1, and 3 doses of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation on Day 57, Day 113 and Day 169.
Biological: ChAd155-hIi-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

Biological: HBc-HBs/AS01B-4 high dose formulation
Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Biological: MVA-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.
Active Comparator: Step C: Group C2
Participants were scheduled to receive two co-administered doses of placebo on Day 1, two co-administered doses of placebo on Day 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation on Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation on Day 169.
Drug: Placebo
Participants in group A3 were scheduled to receive four doses of placebo, one each on Days 1, 57, 113 and 169 and participants in group B3 were scheduled to receive two doses of placebo one each on Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C2 were scheduled to receive two co-administered doses of placebo on Day 1 and two co-administered doses of placebo on Day 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Biological: ChAd155-hIi-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

Biological: HBc-HBs/AS01B-4 high dose formulation
Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Biological: MVA-HBV high dose formulation

Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.

Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 1
Time Frame: Within 7 days after vaccination 1 occurring on Day 1

Assessed solicited administration site events included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

The below presented data is read as follows:

  • For Step C: Group C1, Vaccine A = ChAd155-hIi-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
  • For Step C: Group C2, Vaccine A = Placebo / Vaccine B = Placebo.
Within 7 days after vaccination 1 occurring on Day 1
Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 2
Time Frame: Within 7 days after vaccination 2 occurring on Day 57

Assessed solicited administration site events included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

The below presented data is read as follows:

  • For Step C: Group C1, Vaccine A = MVA-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
  • For Step C: Group C2, Vaccine A = Placebo / Vaccine B = Placebo.
Within 7 days after vaccination 2 occurring on Day 57
Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 3
Time Frame: Within 7 days after vaccination 3 occurring on Day 113

Assessed solicited administration site events included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

The below presented data is read as follows:

  • For step C: Group C1, Vaccine A = MVA-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
  • For step C: Group C2, Vaccine A = ChAd155-hIi-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
Within 7 days after vaccination 3 occurring on Day 113
Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 4
Time Frame: Within 7 days after vaccination 4 occurring on Day 169

Assessed solicited administration site events included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade.

The below presented data is read as follows:

  • For Step C: Group C1, Vaccine A = MVA-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
  • For Step C: Group C2, Vaccine A = MVA-HBV high dose formulation / Vaccine B = HBc-HBs-AS01B high dose formulation.
Within 7 days after vaccination 4 occurring on Day 169
Number of Participants Reporting Any Solicited Systemic Events After Vaccination 1
Time Frame: Within 7 days after vaccination 1 occurring on Day 1
Assessed solicited systemic events included chills, fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia and fever. Fever is defined as oral temperature greater than or equal to (>=) 38.0°C/100.4°F. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 7 days after vaccination 1 occurring on Day 1
Number of Participants Reporting Any Solicited Systemic Events After Vaccination 2
Time Frame: Within 7 days after vaccination 2 occurring on Day 57
Assessed solicited systemic events included chills, fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia and fever. Fever is defined as oral temperature >=38.0°C/100.4°F. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 7 days after vaccination 2 occurring on Day 57
Number of Participants Reporting Any Solicited Systemic Events After Vaccination 3
Time Frame: Within 7 days after vaccination 3 occurring on Day 113
Assessed solicited systemic events included chills, fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia and fever. Fever is defined as oral temperature >=38.0°C/ 100.4°F. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 7 days after vaccination 3 occurring on Day 113
Number of Participants Reporting Any Solicited Systemic Events After Vaccination 4
Time Frame: Within 7 days after vaccination 4 occurring on Day 169
Assessed solicited systemic events included chills, fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia and fever. Fever is defined as oral temperature >=38.0°C/100.4°F. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 7 days after vaccination 4 occurring on Day 169
Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After Vaccination 1
Time Frame: Within 30 days after vaccination 1 occurring on Day 1
An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 30 days after vaccination 1 occurring on Day 1
Number of Participants Reporting Any Unsolicited AEs After Vaccination 2
Time Frame: Within 30 days after vaccination 2 occurring on Day 57
An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 30 days after vaccination 2 occurring on Day 57
Number of Participants Reporting Any Unsolicited AEs After Vaccination 3
Time Frame: Within 30 days after vaccination 3 occurring on Day 113
An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 30 days after vaccination 3 occurring on Day 113
Number of Participants Reporting Any Unsolicited AEs After Vaccination 4
Time Frame: Within 30 days after vaccination 4 occurring on Day 169
An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Within 30 days after vaccination 4 occurring on Day 169
Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 1
Time Frame: Within 30 days after vaccination 1 occurring on Day 1

The assessed parameters were:

  • hematological: haemoglobin decrease, white blood cells (WBCs) increase, WBCs decrease, lymphocytes decrease, neutrophils decrease, eosinophils increase, platelets decrease, prothrombin international normalized ratio (INR) increase;
  • biochemical: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, gamma glutamyl transferase (GGT), creatinine;
  • urinalysis: protein, glucose, red blood cells (RBCs). The grading of the parameters was derived from the standard FDA toxicity grading scale.

The results are defined as follows: <parameter>,<grade at baseline [pre-vaccination (Day 1)]>,<grade post-baseline> (e.g. ALT, Grade 0, Grade 0), where Grade 0 = a non-missing parameter value for which grade could not be derived according to the grading scale and does not belong to Grade 1-4; Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life-Threatening.
Within 30 days after vaccination 1 occurring on Day 1
Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 2
Time Frame: Within 30 days after vaccination 2 occurring on Day 57

The assessed parameters were:

  • hematological: haemoglobin decrease, WBCs increase, WBCs decrease, lymphocytes decrease, neutrophils decrease, eosinophils increase, platelets decrease, prothrombin INR increase;
  • biochemical: ALT, AST, ALP, total bilirubin, GGT, creatinine;
  • urinalysis: protein, glucose, RBCs. The grading of the parameters was derived from the standard FDA toxicity grading scale.

The results are defined as follows: <parameter>,<grade at baseline [pre-vaccination (Day 1)]>,<grade post-baseline> (e.g. ALT, Grade 0, Grade 0), where Grade 0 = a non-missing parameter value for which grade could not be derived according to the grading scale and does not belong to Grade 1-4; Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life-Threatening. Not done = parameter value missing for the specified parameter.
Within 30 days after vaccination 2 occurring on Day 57
Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 3
Time Frame: Within 30 days after vaccination 3 occurring on Day 113

The assessed parameters were:

  • hematological: haemoglobin decrease, WBCs increase, WBCs decrease, lymphocytes decrease, neutrophils decrease, eosinophils increase, platelets decrease, prothrombin INR increase;
  • biochemical: ALT, AST, ALP, total bilirubin, GGT, creatinine;
  • urinalysis: protein, glucose, RBCs. The grading of the parameters was derived from the standard FDA toxicity grading scale.

The results are defined as follows: <parameter>,<grade at baseline [pre-vaccination (Day 1)]>,<grade post-baseline> (e.g. ALT, Grade 0, Grade 0), where Grade 0 = a non-missing parameter value for which grade could not be derived according to the grading scale and does not belong to Grade 1-4; Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life-Threatening.
Within 30 days after vaccination 3 occurring on Day 113
Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 4
Time Frame: Within 30 days after vaccination 4 occurring on Day 169

The assessed parameters were:

  • hematological: haemoglobin decrease, WBCs increase, WBCs decrease, lymphocytes decrease, neutrophils decrease, eosinophils increase, platelets decrease, prothrombin INR increase;
  • biochemical: ALT, AST, ALP, total bilirubin, GGT, creatinine;
  • urinalysis: protein, glucose, RBCs. The grading of the parameters was derived from the standard FDA toxicity grading scale.

The results are defined as follows: <parameter>,<grade at baseline [pre-vaccination (Day 1)]>,<grade post-baseline> (e.g. ALT, Grade 0, Grade 0), where Grade 0 = a non-missing parameter value for which grade could not be derived according to the grading scale and does not belong to Grade 1-4; Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life-Threatening.
Within 30 days after vaccination 4 occurring on Day 169
Number of Participants Reporting Serious Adverse Events (SAEs)
Time Frame: From Day 1 until Day 337
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment.
From Day 1 until Day 337
Number of Participants Reporting Potential Immune-mediated Diseases (pIMDs)
Time Frame: From Day 1 until Day 337
pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
From Day 1 until Day 337
Number of Participants Reporting Liver Disease-related (LDR) Adverse Events of Special Interest (AESIs)
Time Frame: From Day 1 until Day 337

LDR AESIs are defined as adverse events related to the underlying chronic HBV infection and characterized by one or more of the following:

  • ALT flares: Elevation of ALT > 3 X Upper Limit of Normal (ULN): Mild: > 3-5 X ULN, Moderate: > 5-10 X ULN, Severe: > 10 X ULN.
  • ALT flares with other substantial biochemical changes: Bilirubin >= 2 X ULN, And/or INR >1.5.
  • Hepatic decompensation: occurrence of one or more of the following events: ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, variceal bleeding, or hepatic encephalopathy.
  • HBV-Deoxyribonucleic Acid (DNA) breakthrough: any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels 10-fold the Lower Limit of Quantification (LLOQ) of the viral load after HBV DNA was undetectable.
From Day 1 until Day 337
Number of Participants Reporting Hematological AESIs
Time Frame: From Day 1 until Day 337

Hematological AESIs are defined as:

  • spontaneous local or general bleeding with thrombocytes <50,000 platelets/cubic millimeter (mm^3),
  • anemia with hemoglobin (Hgb) <9.5 gram/deciliter (g/dL).
From Day 1 until Day 337
Number of Participants Reporting Medically-attended Adverse Events (MAEs)
Time Frame: From Day 1 until Day 337
MAEs are defined as events for which the participant received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.
From Day 1 until Day 337

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Seropositive Participants for Anti-hepatitis B Core Antibody (Anti-HBc)
Time Frame: At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
A seropositive participant is defined as a participant whose anti-HBc antibody concentration is greater than or equal to (>=) the defined cut-off value.
At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Anti-HBc Antibody Concentrations
Time Frame: At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Anti-HBc antibody concentrations were expressed as geometric mean concentrations (GMCs) in international units per milliliter (IU/mL).
At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Seroconversion
Time Frame: At Days 1,15, 71, 113, 127, 183, 337, 505 and 841
Seroconversion is defined as the appearance of anti-HBs antibodies [i.e., anti-HBs antibody concentrations greater than or equal to (>=) the defined cut-off value] in the serum of participants seronegative [i.e., anti-HBs antibody concentrations below (<) the defined cut-off value] before the study intervention administration.
At Days 1,15, 71, 113, 127, 183, 337, 505 and 841
Anti-HBs Antibody Concentrations
Time Frame: At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Anti-HBs antibody concentrations were determined by total Ig chemiluminescent immunoassay (CLIA) and expressed as GMCs in milli international units per milliliter (mIU/mL).
At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Number of Participants With Anti-HBs Antibody Concentration >=10 mIU/mL
Time Frame: At Days 1,15, 71, 113, 127, 183, 337, 505 and 841
The number of participants with anti-HBs antibody concentrations >=10 mIU/mL is reported.
At Days 1,15, 71, 113, 127, 183, 337, 505 and 841
Number of Participants With Anti-HBs Antibody Concentration >=100 mIU/mL
Time Frame: At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
The number of participants with anti-HBs antibody concentrations >=100 mIU/mL is reported.
At Days 1, 15, 71, 113, 127, 183, 337, 505 and 841
Frequency of HBs-specific CD4+ T-cells
Time Frame: At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBs-specific CD4+ T-cells expressing at least 2 activation markers (among CD40 Ligand [CD40L], 4-1BB, Interleukin-2 [IL-2], Tumour Necrosis Factor alpha [TNF-α], Interferon gamma [IFN-γ], interleukin-17 [IL-17], interleukin-13 [IL-13]) including at least 1 cytokine (among IL-2, TNF-α, IFN-γ, IL-17, IL-13) was determined by cytokine flow cytometry (CFC) and expressed in CD4+ T-cells/million cells.
At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBs-specific CD8+ T-cells
Time Frame: At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBs-specific CD8+ T-cells expressing at least 2 activation markers (among CD40L, 4-1BB, IL-2, TNF-α, IFN-γ, IL-17, IL-13) including at least 1 cytokine (among IL-2, TNF-α, IFN-γ, IL-17, IL-13) was determined by CFC and expressed in CD8+ T-cells/million cells.
At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBc-specific CD4+ T-cells
Time Frame: At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBc-specific CD4+ T-cells expressing at least 2 activation markers (among CD40L, 4-1BB, IL-2, TNF-α, IFN-γ, IL-17, IL-13) including at least 1 cytokine (among IL-2, TNF-α, IFN-γ, IL-17, IL-13) was determined by CFC and expressed in CD4+ T-cells/million cells.
At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBc-specific CD8+ T-cells
Time Frame: At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Frequency of HBc-specific CD8+ T-cells expressing at least 2 activation markers (among CD40L, 4-1BB, IL-2, TNF-α, IFN-γ, IL-17, IL-13) including at least 1 cytokine (among IL-2, TNF-α, IFN-γ, IL-17, IL-13) was determined by CFC and expressed in CD8+ T-cells/million cells.
At Days 1, 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841
Number of Responders for HBs-specific CD4+ T-cells at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
HBs-specific CD4+ T-cell responder is defined as a participant with post-vaccination / pre-vaccination (Day 1) ratio in CD4+ T-cells polypositive response above the maximum ratio observed into placebo controls.
At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
Number of Responders for HBs-specific CD8+ T-cells at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
HBs-specific CD8+ T-cell responder is defined as a participant with post-vaccination / pre-vaccination (Day 1) ratio in CD8+ T-cells polypositive response above the maximum ratio observed into placebo controls.
At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
Number of Responders for HBc-specific CD4+ T-cells at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
HBc-specific CD4+ T-cell responder is defined as a participant with post-vaccination / pre-vaccination (Day 1) ratio in CD4+ T-cells polypositive response above the maximum ratio observed into placebo controls.
At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
Number of Responders for HBc-specific CD8+ T-cells at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
HBc-specific CD8+ T-cell responder is defined as a participant with post-vaccination / pre-vaccination (Day 1) ratio in CD8+ T-cells polypositive response above the maximum ratio observed into placebo controls.
At Days 15, 57, 64, 71, 113, 127, 169, 183, 337, 505 and 841 compared to pre-vaccination (Day 1)
Number of Participants With ≥ 0.5 Log Decrease of qHBsAg at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
The number of participants who achieved ≥0.5 log qHBsAg decrease at the specified timepoints compared to pre-vaccination (Day 1) is reported.
At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
Number of Participants With ≥ 1 Log Decrease of qHBsAg at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
The number of participants who achieved ≥1 log qHBsAg decrease at the specified time points compared to pre-vaccination (Day 1) is reported.
At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
Number of Participants With qHBsAg Loss at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
qHBsAg loss is defined as qHBsAg concentration <0.05 IU/mL.
At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
Number of Participants With Any Log-changes in qHBsAg at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
The number of participants who achieved any log-changes in qHBsAg at the specified time points compared to pre-vaccination (Day 1) is reported.
At Days 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841 compared to pre-vaccination (Day 1)
Number of Participants With qHBsAg Loss and Anti-HBs Seroconversion at the Specified Time Points Compared to Pre-vaccination (Day 1)
Time Frame: At Days 113, 337, 505 and 841 compared to pre-vaccination (Day 1)

qHBsAg loss is defined as qHBsAg concentration <0.05 IU/mL. Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., anti-HBs antibody concentrations >= the defined cut-off value) in the serum of participants seronegative (i.e., anti-HBs antibody concentrations < the defined cut-off value) before the study intervention administration.

A participant was counted only when both qHBsAg loss and anti-HBs seroconversion were reported for the participant.
At Days 113, 337, 505 and 841 compared to pre-vaccination (Day 1)
Evaluation of qHBsAg Geometric Mean Concentrations
Time Frame: At Days 1, 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841
qHBsAg geometric mean concentrations are expressed in IU/mL.
At Days 1, 31, 57, 87, 113, 143, 169, 199, 225, 281, 337, 421, 505, 673, 841
Number of Participants Reporting Any SAEs and SAEs Causally Related to an Investigational Vaccine
Time Frame: From Day 1 until Day 841
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. SAE causally related to an investigational vaccine = SAE assessed by the investigator as causally related to the study vaccination.
From Day 1 until Day 841
Number of Participants Reporting MAEs
Time Frame: From Day 1 until Day 841
MAEs are defined as events for which the participant received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.
From Day 1 until Day 841
Number of Participants Reporting pIMDs
Time Frame: From Day 1 until Day 841
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
From Day 1 until Day 841
Number of Participants Reporting LDR AESIs
Time Frame: From Day 1 until Day 841

LDR AESIs are defined as AEs related to the underlying chronic HBV infection and characterized by one or more of the following:

  • ALT flares: Elevation of ALT > 3 X ULN: Mild: > 3-5 X ULN, Moderate: > 5-10 X ULN, Severe: > 10 X ULN.
  • ALT flares with other substantial biochemical changes: Bilirubin >= 2 X ULN, And/or INR >1.5.
  • Hepatic decompensation: occurrence of one or more of the following events: ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, variceal bleeding, or hepatic encephalopathy.
  • HBV-DNA breakthrough: any increase in serum HBV DNA by >1 log10 from nadir or redetection of serum HBV DNA at levels 10-fold the LLOQ of the viral load after HBV DNA was undetectable.
From Day 1 until Day 841
Number of Participants Reporting Spontaneous Local or General Bleeding With Thrombocytopenia
Time Frame: From Day 1 until Day 841
The number of participants with spontaneous local or general bleeding with thrombocytopenia [<50,000 platelets per cubic milliliter (mm^3)] is reported.
From Day 1 until Day 841
Number of Participants Reporting Anemia
Time Frame: From Day 1 until Day 841
The number of participants with anemia [Hemoglobin (Hgb) <9.5 grams per deciliter (g/dL)] is reported.
From Day 1 until Day 841
Number of Participants Reporting AEs/SAEs Leading to Study Withdrawal
Time Frame: From Day 1 until Day 841
The number of participants who experienced at least one AE or SAE leading to withdrawal is reported. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.
From Day 1 until Day 841
Number of Participants Reporting Pregnancies
Time Frame: From Day 1 until Day 841
The number of participants who experienced pregnancy while participating in this study is reported.
From Day 1 until Day 841
Number of Participants With Outcomes of Reported Pregnancies
Time Frame: From Day 1 until Day 841
The participants with confirmed pregnancies were to be followed up to determine the outcomes of the reported pregnancies.
From Day 1 until Day 841

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2019

Primary Completion (Actual)

October 7, 2024

Study Completion (Actual)

October 7, 2024

Study Registration Dates

First Submitted

March 5, 2019

First Submitted That Met QC Criteria

March 5, 2019

First Posted (Actual)

March 7, 2019

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 3, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 204852
  • 2017-001452-55 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD for this study will be made available via the Clinical Study Data Request site.

IPD Sharing Time Frame

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study

IPD Sharing Access Criteria

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe